Taiho & Cullinan Zipalertinib Meets Primary Endpoint In NSCLC Trial
28 Jan 2025 //
PR NEWSWIRE
Cullinan`s Zipalertinib Shows Positive Pivotal Phase 2b REZILIENT1 Data
01 Jun 2024 //
GLOBENEWSWIRE
REZILIENT3 Global First-Line Trial of Zipalertinib Launched for NSCLC
03 Aug 2023 //
PR NEWSWIRE